Jean-Yves Douillard MD, PhD
Professor Emeritus, Medical Oncology, University of Nantes; Senior Advisor, Integrated Centers of Oncology (ICO), Nantes, FranceDr. Jean-Yves Douillard is a leading international expert in lung cancer and gastrointestinal oncology, and, over the course of a long career, he has held a number of leadership positions, including at the University of Nantes, where he was Professor in Medical Oncology, and at the Integrated Centers of Oncology (ICO) in Nantes, as Head of the Medical Oncology Department and later as Director of Clinical and Translational Research. He has also held senior ESMO positions, serving as Educational Committee Chair and as a member of the Executive Board.
Throughout his career, Dr. Douillard has led clinical trials in lung cancer and gastrointestinal tumors and has investigated targeted therapies, publishing his work in leading scientific journals. His clinical interests also include early drug development and translational research.
Currently, Dr. Doullard is serving as Senior Advisor in early clinical trial research at the Integrated Centers of Oncology.
Recent Contributions to PracticeUpdate:
- 2024 Top Story in Oncology: Perioperative Chemoimmunotherapy for Lung Cancer
- Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
- Long-Term Outcomes After Perioperative Chemotherapy and Nivolumab for NSCLC
- ESMO 2024: Recommendations From Dr. Jean-Yves Douillard for Lung Cancer
- Tepotinib for Advanced Solid Cancers Harboring MET Exon 14 Skipping Mutations or Amplifications
- Brigatinib for ROS1 Fusion–Positive NSCLC
- Efficacy and Safety of 80-mg Osimertinib in Patients With Leptomeningeal Metastases Associated With EGFR-Mutated NSCLC
- ASCO 2024: Abstract Recommendations From Dr. Jean-Yves Douillard for Lung Cancer
- Iruplinalkib vs Crizotinib for ALK TKI–Naïve Locally Advanced or Metastatic ALK-Positive NSCLC
- 2023 Top Story in Oncology: Immune Checkpoint Inhibitors for Resectable Lung Cancer